These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1884 related articles for article (PubMed ID: 26552419)

  • 21. Clinicopathologic Comparison of Lynch Syndrome-associated and "Lynch-like" Endometrial Carcinomas Identified on Universal Screening Using Mismatch Repair Protein Immunohistochemistry.
    Mills AM; Sloan EA; Thomas M; Modesitt SC; Stoler MH; Atkins KA; Moskaluk CA
    Am J Surg Pathol; 2016 Feb; 40(2):155-65. PubMed ID: 26523542
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of clinical schemas and morphologic features in predicting Lynch syndrome in mutation-positive patients with endometrial cancer encountered in the context of familial gastrointestinal cancer registries.
    Ryan P; Mulligan AM; Aronson M; Ferguson SE; Bapat B; Semotiuk K; Holter S; Kwon J; Kalloger SE; Gilks CB; Gallinger S; Pollett A; Clarke BA
    Cancer; 2012 Feb; 118(3):681-8. PubMed ID: 21721000
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Comprehensive assessment of mismatch repair and microsatellite instability status in molecular classification of endometrial carcinoma].
    Liu Y; Wang YX; Sun XJ; Ting X; Wu R; Liu XD; Liu CR
    Zhonghua Fu Chan Ke Za Zhi; 2023 Oct; 58(10):755-765. PubMed ID: 37849256
    [No Abstract]   [Full Text] [Related]  

  • 24. The proportion of endometrial tumours associated with Lynch syndrome (PETALS): A prospective cross-sectional study.
    Ryan NAJ; McMahon R; Tobi S; Snowsill T; Esquibel S; Wallace AJ; Bunstone S; Bowers N; Mosneag IE; Kitson SJ; O'Flynn H; Ramchander NC; Sivalingam VN; Frayling IM; Bolton J; McVey RJ; Evans DG; Crosbie EJ
    PLoS Med; 2020 Sep; 17(9):e1003263. PubMed ID: 32941469
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clustering of Lynch syndrome malignancies with no evidence for a role of DNA mismatch repair.
    Case AS; Zighelboim I; Mutch DG; Babb SA; Schmidt AP; Whelan AJ; Thibodeau SN; Goodfellow PJ
    Gynecol Oncol; 2008 Feb; 108(2):438-44. PubMed ID: 18022218
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Universal Lynch Syndrome Screening Should be Performed in All Upper Tract Urothelial Carcinomas.
    Ju JY; Mills AM; Mahadevan MS; Fan J; Culp SH; Thomas MH; Cathro HP
    Am J Surg Pathol; 2018 Nov; 42(11):1549-1555. PubMed ID: 30148743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer.
    Pérez-Carbonell L; Ruiz-Ponte C; Guarinos C; Alenda C; Payá A; Brea A; Egoavil CM; Castillejo A; Barberá VM; Bessa X; Xicola RM; Rodríguez-Soler M; Sánchez-Fortún C; Acame N; Castellví-Bel S; Piñol V; Balaguer F; Bujanda L; De-Castro ML; Llor X; Andreu M; Carracedo A; Soto JL; Castells A; Jover R
    Gut; 2012 Jun; 61(6):865-72. PubMed ID: 21868491
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunohistochemical expression pattern of MMR protein can specifically identify patients with colorectal cancer microsatellite instability.
    Amira AT; Mouna T; Ahlem B; Raoudha A; Majid BH; Amel H; Rachida Z; Nadia K
    Tumour Biol; 2014 Jul; 35(7):6283-91. PubMed ID: 24643686
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ovarian endometrioid adenocarcinoma: incidence and clinical significance of the morphologic and immunohistochemical markers of mismatch repair protein defects and tumor microsatellite instability.
    Aysal A; Karnezis A; Medhi I; Grenert JP; Zaloudek CJ; Rabban JT
    Am J Surg Pathol; 2012 Feb; 36(2):163-72. PubMed ID: 22189970
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of mismatch-repair/microsatellite instability-discordant endometrial cancers.
    Riedinger CJ; Esnakula A; Haight PJ; Suarez AA; Chen W; Gillespie J; Villacres A; Chassen A; Cohn DE; Goodfellow PJ; Cosgrove CM
    Cancer; 2024 Feb; 130(3):385-399. PubMed ID: 37751191
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lessons learnt from implementation of a Lynch syndrome screening program for patients with gynaecological malignancy.
    Najdawi F; Crook A; Maidens J; McEvoy C; Fellowes A; Pickett J; Ho M; Nevell D; McIlroy K; Sheen A; Sioson L; Ahadi M; Turchini J; Clarkson A; Hogg R; Valmadre S; Gard G; Dooley SJ; Scott RJ; Fox SB; Field M; Gill AJ
    Pathology; 2017 Aug; 49(5):457-464. PubMed ID: 28669579
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer.
    Southey MC; Jenkins MA; Mead L; Whitty J; Trivett M; Tesoriero AA; Smith LD; Jennings K; Grubb G; Royce SG; Walsh MD; Barker MA; Young JP; Jass JR; St John DJ; Macrae FA; Giles GG; Hopper JL
    J Clin Oncol; 2005 Sep; 23(27):6524-32. PubMed ID: 16116158
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Constitutional Mismatch Repair Deficiency in Israel: High Proportion of Founder Mutations in MMR Genes and Consanguinity.
    Baris HN; Barnes-Kedar I; Toledano H; Halpern M; Hershkovitz D; Lossos A; Lerer I; Peretz T; Kariv R; Cohen S; Half EE; Magal N; Drasinover V; Wimmer K; Goldberg Y; Bercovich D; Levi Z
    Pediatr Blood Cancer; 2016 Mar; 63(3):418-27. PubMed ID: 26544533
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Four novel germline mutations in the MLH1 and PMS2 mismatch repair genes in patients with hereditary nonpolyposis colorectal cancer.
    Montazer Haghighi M; Radpour R; Aghajani K; Zali N; Molaei M; Zali MR
    Int J Colorectal Dis; 2009 Aug; 24(8):885-93. PubMed ID: 19479271
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is tumor testing efficiency for Lynch syndrome different in rectal and colon cancer?
    Marabelli M; Gandini S; Rafaniello PR; Calvello M; Tolva G; Feroce I; Lazzeroni M; Marino E; Dal Molin M; Trovato C; Guerrieri-Gonzaga A; Petz WL; Barberis M; Bertario L; Bonanni B
    Dig Liver Dis; 2020 Dec; 52(12):1503-1511. PubMed ID: 32620519
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Screening for germline mismatch repair mutations following diagnosis of sebaceous neoplasm.
    Everett JN; Raymond VM; Dandapani M; Marvin M; Kohlmann W; Chittenden A; Koeppe E; Gustafson SL; Else T; Fullen DR; Johnson TM; Syngal S; Gruber SB; Stoffel EM
    JAMA Dermatol; 2014 Dec; 150(12):1315-21. PubMed ID: 25006859
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Point: justification for Lynch syndrome screening among all patients with newly diagnosed colorectal cancer.
    Hampel H
    J Natl Compr Canc Netw; 2010 May; 8(5):597-601. PubMed ID: 20495086
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective evaluation of molecular screening for Lynch syndrome in patients with endometrial cancer ≤ 70 years.
    Leenen CH; van Lier MG; van Doorn HC; van Leerdam ME; Kooi SG; de Waard J; Hoedemaeker RF; van den Ouweland AM; Hulspas SM; Dubbink HJ; Kuipers EJ; Wagner A; Dinjens WN; Steyerberg EW
    Gynecol Oncol; 2012 May; 125(2):414-20. PubMed ID: 22306203
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epigenetic mechanisms in the pathogenesis of Lynch syndrome.
    Peltomäki P
    Clin Genet; 2014 May; 85(5):403-12. PubMed ID: 24443998
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Yield of routine molecular analyses in colorectal cancer patients ≤70 years to detect underlying Lynch syndrome.
    van Lier MG; Leenen CH; Wagner A; Ramsoekh D; Dubbink HJ; van den Ouweland AM; Westenend PJ; de Graaf EJ; Wolters LM; Vrijland WW; Kuipers EJ; van Leerdam ME; Steyerberg EW; Dinjens WN;
    J Pathol; 2012 Apr; 226(5):764-74. PubMed ID: 22081473
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 95.